Professor Udai Banerji is a medical oncologist associated with The Royal Marsden and is listed as a consultant within the hospital's Drug Development Unit. The DDU focuses on Phase I cancer drug trials, making it an important part of The Royal Marsden's clinical research programme.

His professional work sits at the intersection of medical oncology and cancer research. Early-phase studies investigate new medicines and treatment strategies, with particular emphasis on evaluating safety, appropriate dosing and potential effectiveness before treatments progress through later stages of clinical development.

The Royal Marsden's Drug Development Unit operates through a multidisciplinary structure. Patients participating in clinical trials receive specialist medical supervision alongside support from research nurses, study managers and other healthcare professionals. This coordinated model is important for the careful monitoring required during early-phase studies.

Professor Banerji's association with the DDU is relevant for patients looking for specialist cancer research and clinical-trial services in London. However, participation in a clinical trial is not automatically suitable for every patient. Eligibility can depend on tumour type, molecular characteristics, previous treatment, general health and the specific requirements of an individual study.

For international patients, clinical-trial planning can require additional medical documentation and specialist review. Patients may need pathology reports, imaging, treatment histories and other clinical information before an oncology team can determine whether a research programme may be appropriate.

The Royal Marsden's recent patient information lists Professor Banerji among the consultants in its Drug Development Unit together with Professor Johann de Bono, Dr Juanita Lopez, Dr Anna Minchom, Dr Adam Sharp and Dr Alec Paschalis.

For an online medical directory, Professor Udai Banerji's profile can appropriately focus on medical oncology, cancer research, early-phase clinical trials and drug development. These areas reflect the clinical-research environment in which he is currently listed.

Patients seeking treatment should distinguish between a doctor's research role and the treatments routinely available to patients. A clinical trial follows a defined research protocol, while standard oncology care follows established clinical practice. The treating team can explain which options are relevant to an individual diagnosis.

The Royal Marsden remains an important specialist setting for cancer treatment and research in the United Kingdom. Consultant-led multidisciplinary care allows patients to be assessed within specialist services according to their diagnosis and treatment needs.

Before arranging treatment, patients should confirm the consultant's current availability, referral pathway and whether any relevant clinical trials are open. Clinical-trial availability changes over time, so information should be checked directly with the hospital.